Detalles de la búsqueda
1.
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Am J Kidney Dis
; 77(1): 23-34.e1, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32971190
2.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
N Engl J Med
; 377(20): 1930-1942, 2017 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29105594
3.
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Kidney Int
; 96(1): 159-169, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30898339
4.
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Nephrol Dial Transplant
; 33(3): 477-489, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28379536
5.
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Nephrol Dial Transplant
; 33(4): 645-652, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28992127
6.
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
J Am Soc Nephrol
; 28(5): 1592-1602, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27920153
7.
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Am J Kidney Dis
; 69(2): 210-219, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27856088
8.
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Am J Nephrol
; 45(3): 257-266, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28166521
9.
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
Nephrol Dial Transplant
; 32(8): 1356-1363, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27325254
10.
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.
Nephrol Dial Transplant
; 32(6): 969-975, 2017 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27190355
11.
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.
J Digit Imaging
; 30(4): 442-448, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28550374
12.
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Nephrol Dial Transplant
; 32(7): 1262, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28444221
13.
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
J Am Coll Cardiol
; 80(18): 1721-1731, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36302584
14.
A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity.
J Biol Chem
; 285(27): 20993-1003, 2010 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-20442408
15.
Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy.
Diabetes Ther
; 12(2): 499-508, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33340064
16.
Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
Adv Ther
; 38(8): 4425-4441, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34254257
17.
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress.
Mol Cell Biol
; 26(24): 9517-32, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17030613
18.
Analysis of Nationwide Data to Determine the Incidence and Diagnosed Prevalence of Autosomal Dominant Polycystic Kidney Disease in the USA: 2013-2015.
Kidney Dis (Basel)
; 5(2): 107-117, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31019924
19.
Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease.
Clin Kidney J
; 12(1): 71-77, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30746130
20.
Activating transcription factor 4 is translationally regulated by hypoxic stress.
Mol Cell Biol
; 24(17): 7469-82, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15314157